Naveet Pannu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naveet Pannu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Archana Bhatnagar
Department of Biochemistry, Panjab University, BMS-Block II, South Campus, Chandigarh 160014, India
4 shared publications A Bhatnagar
Panjab University, Biochemistry, Chandigarh, India
1 shared publication- Ana B. Fraga-Timiraos
Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada
1 shared publication - Anne-Laure Larroque
The Research Institute of the McGill University Health Center, Montreal, QC H4A 3J1, Canada
1 shared publication - Antonio Aliaga
Cancer Drug Research Laboratory, The Research Institute of the McGill University Health Center (RI-MUHC), Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H4A 3J1, Canada
1 shared publication - Bertrand J. Jean-Claude
Cancer Drug Research Laboratory, Department of Medicine, Division of Medical Oncology, McGill University/Royal Victoria Hospital, Montreal, Quebec, Canada and
1 shared publication
Latest Publications
- Open Access
Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model
Background: ZR2002 is a dual EGFR-DNA-targeting combi-molecule that carries a chloroethyl group at the six-position of the quinazoline ring designed to alkylate DNA. Despite its good pharmacokinetics, ZR2002 is metabolized in vivo into dechlorinated metabolites, losing the DNA-alkylating function required to damage DNA. To increase the DNA damage activity in tumor cells in vivo, we compared ZR2002 with two of its 6-N,N-disubstituted analogs: “JS61”, with a nitrogen mustard function at the six-position of the quinazoline ring, and “JS84”, with an N-methyl group. Methods: Tumor xenografts were performed with the human Saos-2 osteosarcoma cell line expressing EGFR. Mice were treated with ZR2002, JS84 or JS61, and the tumor burden was measured with a caliper and CT/PET imaging. Drug metabolism was analyzed with LC-MS. EGFR and ɣ-H2AX phosphorylation were quantified via Western blot analysis and immunohistochemistry. Results: In vivo analysis showed that significant tumor growth inhibition was only achieved when ZR2002 was administered in its naked form. The metabolic dealkylation of JS61 and JS84 did not release sufficient concentrations of ZR2002 for the intratumoral inhibition of P-EGFR or enhanced levels of P-H2AX. Conclusions: The results in toto suggest that intratumoral concentrations of intact ZR2002 are correlated with the highest inhibition of P-EGFR and induction of DNA damage in vivo. ZR2002 may well represent a good drug candidate for the treatment of EGFR-expressing osteosarcoma.
Open AccessMolecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model
Background: ZR2002 is a dual EGFR-DNA-targeting combi-molecule that carries a chloroethyl group at the six-position of the quinazoline ring designed to alkylate DNA. Despite its good pharmacokinetics, ZR2002 is metabolized in vivo into dechlorinated metabolites, losing the DNA-alkylating function required to damage DNA. To increase the DNA damage activity in tumor cells in vivo, we compared ZR2002 with two of its 6-N,N-disubstituted analogs: “JS61”, with a nitrogen mustard function at the six-position of the quinazoline ring, and “JS84”, with an N-methyl group. Methods: Tumor xenografts were performed with the human Saos-2 osteosarcoma cell line expressing EGFR. Mice were treated with ZR2002, JS84 or JS61, and the tumor burden was measured with a caliper and CT/PET imaging. Drug metabolism was analyzed with LC-MS. EGFR and ɣ-H2AX phosphorylation were quantified via Western blot analysis and immunohistochemistry. Results: In vivo analysis showed that significant tumor growth inhibition was only achieved when ZR2002 was administered in its naked form. The metabolic dealkylation of JS61 and JS84 did not release sufficient concentrations of ZR2002 for the intratumoral inhibition of P-EGFR or enhanced levels of P-H2AX. Conclusions: The results in toto suggest that intratumoral concentrations of intact ZR2002 are correlated with the highest inhibition of P-EGFR and induction of DNA damage in vivo. ZR2002 may well represent a good drug candidate for the treatment of EGFR-expressing osteosarcoma.
- 15 May 2020
- Published by Springer Nature in Inflammopharmacology
- Vol. 28 (3) , 719-735
Prophylactic effect of resveratrol and piperine on pristane-induced murine model of lupus-like disease
Systemic lupus erythematosus is a multisystem autoimmune disease. Apart from usual treatments, approximately 50% of lupus patients use complementary medicine. Resveratrol is a phytoalexin with various pharmacological properties. We hypothesised that prophylactic treatment with resveratrol may abrogate manifestations in pristane-induced murine model of lupus-like disease and piperine; a bio-enhancer of resveratrol may enhance these properties. The prophylactic effect of resveratrol (25 mg/kg body weight: P-Res) alone and in combination with piperine (2.5 mg/kg body weight: P-RP) were assessed. P-Res and P-RP were equally efficient in mitigating oxidative stress (enzyme activity of catalase, superoxide dismutase, glutathione peroxidase and level of reduced glutathione, lipid peroxidation, and reactive oxygen species). Inflammation is associated with an increase in inflammatory cytokines. IL-6 was decreased by 71.60% with P-Res, and TNF-α was reduced by 59.70% with P-Res and 62.66% with P-RP (p < 0.05). Prevention of renal pathologies was evident by reduction in creatinine level by P-RP (p < 0.05) and abrogation of proteinuria (P-Res and P-RP). P-RP was efficient in restoring histopathology of liver and lungs and decreased immune complexes in lungs. P-Res proved more beneficial by extenuating lipogranulomas, histopathological manifestations in kidney, liver, and lungs, and eliminating immune complexes in liver and lungs. None of the treatments could regulate auto-antibody formation. Resveratrol decreases the susceptibility of developing pathogenesis in murine model of lupus-like disease. The results also conclude that addressing the bioavailability of resveratrol using it in combination with piperine does not prove more efficacious in preventing lupus-associated pathologies than resveratrol alone. Graphic abstract
- 15 May 2020
- Published by Springer Nature in Inflammopharmacology
- Vol. 28 (3) , 719-735
Prophylactic effect of resveratrol and piperine on pristane-induced murine model of lupus-like disease
Systemic lupus erythematosus is a multisystem autoimmune disease. Apart from usual treatments, approximately 50% of lupus patients use complementary medicine. Resveratrol is a phytoalexin with various pharmacological properties. We hypothesised that prophylactic treatment with resveratrol may abrogate manifestations in pristane-induced murine model of lupus-like disease and piperine; a bio-enhancer of resveratrol may enhance these properties. The prophylactic effect of resveratrol (25 mg/kg body weight: P-Res) alone and in combination with piperine (2.5 mg/kg body weight: P-RP) were assessed. P-Res and P-RP were equally efficient in mitigating oxidative stress (enzyme activity of catalase, superoxide dismutase, glutathione peroxidase and level of reduced glutathione, lipid peroxidation, and reactive oxygen species). Inflammation is associated with an increase in inflammatory cytokines. IL-6 was decreased by 71.60% with P-Res, and TNF-α was reduced by 59.70% with P-Res and 62.66% with P-RP (p < 0.05). Prevention of renal pathologies was evident by reduction in creatinine level by P-RP (p < 0.05) and abrogation of proteinuria (P-Res and P-RP). P-RP was efficient in restoring histopathology of liver and lungs and decreased immune complexes in lungs. P-Res proved more beneficial by extenuating lipogranulomas, histopathological manifestations in kidney, liver, and lungs, and eliminating immune complexes in liver and lungs. None of the treatments could regulate auto-antibody formation. Resveratrol decreases the susceptibility of developing pathogenesis in murine model of lupus-like disease. The results also conclude that addressing the bioavailability of resveratrol using it in combination with piperine does not prove more efficacious in preventing lupus-associated pathologies than resveratrol alone. Graphic abstract
- 1 January 2020
- Published by Elsevier in Immunobiology
- Vol. 225 (1) , 151871
Oxidative stress and immune complexes: Pathogenic mechanisms in pristane induced murine model of lupus
- 1 January 2020
- Published by Elsevier in Immunobiology
- Vol. 225 (1) , 151871
Oxidative stress and immune complexes: Pathogenic mechanisms in pristane induced murine model of lupus
- 15 November 2019
- Published by Springer Nature in Inflammopharmacology
- Vol. 28 (2) , 401-424
Combinatorial therapeutic effect of resveratrol and piperine on murine model of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic multi-system inflammatory disease associated with autoantibody formation. Clinical management of lupus is a
- 15 November 2019
- Published by Springer Nature in Inflammopharmacology
- Vol. 28 (2) , 401-424
Combinatorial therapeutic effect of resveratrol and piperine on murine model of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic multi-system inflammatory disease associated with autoantibody formation. Clinical management of lupus is a
- Open Access
- 1 January 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 109, 2237-2251
Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases
- 1 January 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 109, 2237-2251
Open AccessResveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases
- Open Access
- 24 March 2017
- Published by BMJ
- Vol. 4 (Suppl 1) , A42.3-A43
102 Inhibitory effect of resveratrol on oxidative stress in murine model of systemic lupus erythematosus
Background and aims Systemic lupus erythematosus is a systemic autoimmune inflammatory disease where therapeutics are associated with various side effects. As dietary factors have been associated in the prevention of different diseases this study aimed to exploit resveratrol, a polyphenol derived from peanuts, grapes, etc as a dietary factor supporting therapeutics by using its antioxidative properties in the management of oxidative stress in a pristane induced murine model of lupus. Methods The model was established by injecting 0.5 ml of pristane intra-peritoneally and oxidative stress was assessed after 6 months. 25 mg/kg body weight of resveratrol was given orally after 2 months of pristane administration daily for the next 4 months. Results The increased level of reactive oxygen species (Mean Flourescence value at 0 month: 1.70±0.22 to 4.89±1.37 at 6 months) in peripheral blood mononuclear cells in the model decreased significantly after resveratrol treatment (1.75±0.21). Pristane treatment decreased the activity of antioxidant enzymes like Catalase in lungs, Superoxide Dismutase in lungs and spleen and Glutathione peroxidase in liver and lungs. Resveratrol increased the activity of all these enzymes and a significant increase was observed in the activity of Superoxide Dismutase in lungs. Pristane treatment decreased the levels of reduced glutathione and increased lipid peroxidation in kidneys, liver, lungs and spleen. Resveratrol treatment restored reduced glutathione level and decreased lipid peroxidation. Comparison of enzyme activity of Catalase, Superoxide Dismutase and Glutathione Peroxide in kidney, Liver, lung and spleen at 0 month, after 6 month pristane treatment and after resveratrol treatment. Values are expressed as Mean±SEM. Catalase Units: μM of H202 decomposed per minute. Superoxide Dismutaes Units: Amount of enzyme which inhibits the rate of reaction by 50% per minute. Glutathoine Peroxidase: μM of NADPH oxidised per minute. Comparision of the levels of reduced glutathione and lipid peroxidation in Kidney, liver, lung and spleen at 0 month, 6 month pristane treatment and after resveratrol treatment. Values are expressed as Mean±SEM. Conclusions In conclusion this study states that, the consumption of resveratrol helps in better management of the disease by combating oxidative stress, the root cause of different manifestations observed in lupus.
- 24 March 2017
- Published by BMJ
- Vol. 4 (Suppl 1) , A42.3-A43
Open Access102 Inhibitory effect of resveratrol on oxidative stress in murine model of systemic lupus erythematosus
Background and aims Systemic lupus erythematosus is a systemic autoimmune inflammatory disease where therapeutics are associated with various side effects. As dietary factors have been associated in the prevention of different diseases this study aimed to exploit resveratrol, a polyphenol derived from peanuts, grapes, etc as a dietary factor supporting therapeutics by using its antioxidative properties in the management of oxidative stress in a pristane induced murine model of lupus. Methods The model was established by injecting 0.5 ml of pristane intra-peritoneally and oxidative stress was assessed after 6 months. 25 mg/kg body weight of resveratrol was given orally after 2 months of pristane administration daily for the next 4 months. Results The increased level of reactive oxygen species (Mean Flourescence value at 0 month: 1.70±0.22 to 4.89±1.37 at 6 months) in peripheral blood mononuclear cells in the model decreased significantly after resveratrol treatment (1.75±0.21). Pristane treatment decreased the activity of antioxidant enzymes like Catalase in lungs, Superoxide Dismutase in lungs and spleen and Glutathione peroxidase in liver and lungs. Resveratrol increased the activity of all these enzymes and a significant increase was observed in the activity of Superoxide Dismutase in lungs. Pristane treatment decreased the levels of reduced glutathione and increased lipid peroxidation in kidneys, liver, lungs and spleen. Resveratrol treatment restored reduced glutathione level and decreased lipid peroxidation. Comparison of enzyme activity of Catalase, Superoxide Dismutase and Glutathione Peroxide in kidney, Liver, lung and spleen at 0 month, after 6 month pristane treatment and after resveratrol treatment. Values are expressed as Mean±SEM. Catalase Units: μM of H202 decomposed per minute. Superoxide Dismutaes Units: Amount of enzyme which inhibits the rate of reaction by 50% per minute. Glutathoine Peroxidase: μM of NADPH oxidised per minute. Comparision of the levels of reduced glutathione and lipid peroxidation in Kidney, liver, lung and spleen at 0 month, 6 month pristane treatment and after resveratrol treatment. Values are expressed as Mean±SEM. Conclusions In conclusion this study states that, the consumption of resveratrol helps in better management of the disease by combating oxidative stress, the root cause of different manifestations observed in lupus.